openPR Logo
Press release

U.S. Compounding Pharmacies Market Global Key Players - Premier Pharmacy Labs, Rx3 Compounding Pharmacy, RXQ Compounding Pharmacy, Triangle Compounding Pharmacies, Wedgewood Village Pharmacy, Wells Pharmacy Network

03-13-2020 11:29 AM CET | Health & Medicine

Press release from: Global Market Insights, Inc.

U.S. Compounding Pharmacies Market

U.S. Compounding Pharmacies Market

Endowed with numerous regulatory compliances, the U.S. compounding pharmacies market has been traversing toward becoming one of the most profitable business spaces. Owing to the lack of safety and absence of clinical clearances, compounded medications have been under stringent scrutiny that has been helping players in the U.S. compounding pharmacies to strengthen their existing manufacturing practices. The surging use of compounded medicines for pain relief and hormone replacement therapies is poised to fuel the product demand over the years ahead. The business tactics adopted by the pharmaceutical companies to proliferate the supply of superior compounded drugs will further propel the industry share.

In U.S, compounded medications are not approved by the FDA so far, indeed, this regulatory agency has been working continuously to encourage compounding pharmacies with the implementation of new policies. Over the last few years, FDA has been dedicatedly striving toward the development of compliances for compounding pharmacies. In fact, recently, it has deployed new guidance documents that describe the fundamental scope, insanitary conditions, and effective inspection procedures required for maintaining the effectiveness and safety after the consumption of drugs. In order to comply with the guidelines provided by the FDA, players in the U.S. compounding pharmacies industry are planning to set up drug formulation workflow processes. The integration of safe handling procedures and effective formulations will further strengthen the U.S. compounding pharmacies industry outlook over the years ahead.

Request sample copy of this report @ https://www.decresearch.com/request-sample/detail/2961

Compounded drugs are important for the patients whose clinical requirement cannot be fulfilled by FDA-approved drugs. The patients suffering from the allergy need medicines without compromising on certain flavoring agents that further fuels the demand for compounded drugs which also play a critical role in case there is a shortage of FDA-approved medication. Say for instance, in the U.S., most of the FDA approved medicines have not been available in a liquid form that is primarily required for the elderly patients and children who cannot swallow pills.

Meanwhile, the main concern related to the compounding pharmacies is the huge number of unchecked compounds that have been largely available in the distribution centers. In accordance, the U.S. government has deployed some reforms that mandates compounding pharmacies to obtain a certification from the Pharmacy Compounding Accreditation Board (PCAB) or another equivalent regulatory body. In addition, the FDA has also sent a letter to the state pharmacy board to encourage outsourcing facilities to register with the FDA.

The registration potentially allows the so-called outsourcing facilities to sell their products in bulk to physicians and hospitals without a prescription for individual patients. Such perks provided by the regulatory bodies for encouraging compound pharmacies is poised to enhance the U.S. compounding pharmacies market size.

Make Inquiry about this report @ https://www.decresearch.com/inquiry-before-buying/2961

Currently, as per the estimates by the American Pharmacists Association, there are nearly 7,500 pharmacies providing compounding services across U.S. The number will increase over the coming years as several smaller firms have been investing in the development of low-risk drugs that will significantly boost U.S. compounding pharmacies market share.

The regulatory compliances implemented by the governing bodies will help pharmacies develop potentially more effective compounded medications on a large scale over the years ahead. The increasing use of compounded medication for overcoming the risks associated with the consumption of regulated drugs on the health of the geriatric and pediatric populace will further expedite the industry size considerably. Powered by the lower manufacturing costs of these medicines, by the end of 2024, U.S. compounding pharmacies market will generate a revenue of more than USD 7 billion.

Table Of Content

Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary

Chapter 2. Executive Summary
2.1. U.S. compounding pharmacies industry 3600 synopsis, 2014 - 2025

Chapter 3. U.S. Compounding Pharmacies Industry Insights
3.1. Industry segmentation
3.2. Industry size and forecast, 2014 - 2025
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Increasing geriatric population and improved longevity
3.3.1.2. Growing acceptance of personalized medicines
3.3.1.3. Increasing drug shortage in the country
3.3.1.4. Convenience of using compounded drugs
3.3.1.5. Growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women
3.3.2. Industry pitfalls & challenges
3.3.2.1. Changing regulatory specifications
3.3.2.2. Issues related to safety standards of compounded drugs
3.4. Growth potential analysis
3.4.1. By pharmacy type
3.4.2. By sterility
3.4.3. By product
3.4.4. By application
3.4.5. By compounding type
3.4.6. By therapeutic area
3.5. Regulatory landscape
3.6. Reimbursement landscape
3.7. Innovative compounding technologies
3.7.1. Web-based quality management system
3.7.2. Digital tools
3.8. Porter's analysis
3.9. Competitive landscape, 2017
3.9.1. Strategy dashboard
3.10. PESTEL analysis

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release U.S. Compounding Pharmacies Market Global Key Players - Premier Pharmacy Labs, Rx3 Compounding Pharmacy, RXQ Compounding Pharmacy, Triangle Compounding Pharmacies, Wedgewood Village Pharmacy, Wells Pharmacy Network here

News-ID: 1966303 • Views: 120

More Releases from Global Market Insights, Inc.

Global sodium metasilicate pentahydrate market size by 2025 | Top Companies are …
Global Market Insights, Inc., says that sodium metasilicate pentahydrate market may exceed USD 875 million by 2025. Sodium metasilicate pentahydrate market is expected to accrue momentous proceeds from the cement industry. The product is used as a connecting agent in the making of refractory cement & can enable properties such as chemical and heat resistance and hardness. It has also found application in the cosmetic, textile, ceramics, chemical production, and
Vinyl ester market Growth in Europe, Impact Covid19 and Top key players like Swa …
Vinyl ester market to be fueled by increasing deployment of wind energy facilities, Europe to emerge as a pivotal revenue pocket. In 2017, Europe marked a growth of 25% in the wind power plant capacity annual installation as compared to 2016. Whereas wind energy was the second-largest source of power generation power in the year 2016 in Europe. Nations worldwide are actively aligning their focus toward the deployment of wind
Biaxially Oriented Polypropylene (BOPP) Market Size, Share by key players like B …
Biaxially oriented polypropylene (BOPP) market size to reach USD 20 billion by 2024. Growing focus on superior packaging for the protection of delicate good, foods, medicines, and others will favor BOPP business growth in the coming years. Rapid proliferation of e-commerce platforms along with changing consumer spending trends will drive biaxially oriented polypropylene (BOPP) market outlook. In a world of constantly-changing lifestyles, consumers expect products to be shatter-proof, lightweight, aesthetically appealing,
Titanium Dioxide Market to see 7%+ CAGR over 2021-2026 | Key Players are Tronox …
Titanium Dioxide Market growth will be driven by rising expansion activities in the paints & coatings sector and proliferating application in paper & pulp industry. For years, titanium dioxide (TiO₂) has been used in the manufacturing of numerous consumer products across various industries. The product finds applications in paints, adhesives, coatings, paper, rubber, printing inks, textiles, coated fabrics, ceramics, roofing materials, floor coverings, and cosmetics. Surging in product demand across

All 5 Releases


More Releases for FDA

FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
11-09-2016 | Science & Education
GRCTS
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding